The rising use of glucagon-like peptide-1 (GLP ... of drug that mimics the glucagon-like peptide-1 hormone. It stimulates insulin secretion and reduces appetite, helping to control blood sugar and ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Although the first GLP-1 drug ... to use on humans. According to postdoc fellow Andreas Lodberg who was one of the ...

Novo Nordisk's GLP-1 receptor ... alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use for the versatile drug class. The small, 48-subject study ...

This retrospective study suggests there is a cardioprotective effect of GLP-1RA compared ... antiarrhythmic drug use, cardioversion, or repeat ablation by 1 year. Similarly, in PULSED AF, around ...

The study, conducted 4,489 of US adults (including 332 currently taking a GLP-1 and 151 no longer on the medication) found that most individuals taking GLP-1s for weight loss do not expect to stay ...

Study presented at DDW ... trial design to support drug development. The study titled, "A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis ...

Higher body appreciation was highlighted as a protective factor against GLP-1 use. However, it is important to note that the study's cross-sectional design means these findings are correlational ...

The rise of GLP-1 weight loss drugs represents a shift in the way consumers ... The Acosta Group study confirms the growing interest in GLP-1 products and shows how this therapeutic option has ...

announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for diabetes and weight loss. The trial of the drug ...